Bide Pharmatech Co. Ltd. A Asset Resilience Ratio
Bide Pharmatech Co. Ltd. A asset resilience ratio. Bide Pharmatech Co. Ltd. A (688073) has an Asset Resilience Ratio of 9.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688073 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bide Pharmatech Co. Ltd. A (2020–2025)
Asset resilience ratio of Bide Pharmatech Co. Ltd. A from 2020 to 2025. This chart shows how Bide Pharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. Read 688073 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bide Pharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Bide Pharmatech Co. Ltd. A balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥240.38 Million | 9.46% |
| Total Liquid Assets | CN¥240.38 Million | 9.46% |
Asset Resilience Insights
- Limited Liquidity: Bide Pharmatech Co. Ltd. A maintains only 9.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bide Pharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Bide Pharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Bide Pharmatech Co. Ltd. A Asset Resilience Ratio by Year (2020–2025)
Bide Pharmatech Co. Ltd. A asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Bide Pharmatech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.97% | CN¥100.01 Million ≈ $14.63 Million |
CN¥2.52 Billion ≈ $368.29 Million |
+0.85pp |
| 2024-12-31 | 3.12% | CN¥75.52 Million ≈ $11.05 Million |
CN¥2.42 Billion ≈ $353.83 Million |
+3.12pp |
| 2023-12-31 | 0.01% | CN¥122.54K ≈ $17.93K |
CN¥2.42 Billion ≈ $353.39 Million |
-0.16pp |
| 2022-12-31 | 0.17% | CN¥3.97 Million ≈ $581.28K |
CN¥2.36 Billion ≈ $345.23 Million |
-7.92pp |
| 2020-12-31 | 8.08% | CN¥43.00 Million ≈ $6.29 Million |
CN¥531.90 Million ≈ $77.83 Million |
-- |
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.